摘要
目的:观察环氧化酶-2抑制剂依托考昔治疗急性痛风性关节炎的疗效和安全性。方法:选择到我院就诊急性痛风发作患者113例,按随机平行对照原则分为治疗组(给予依托考昔120 mg/d,57例)和对照组双氯芬酸钠(双氯芬酸钠组75 mg/d,56例)。两组病人均给与相同的基础治疗如低嘌呤饮食、多饮水、卧床休息、碱化尿液等。选初诊、服药后的第4小时、第2、5天为观察点,对患者病变关节进行疼痛评分和肿胀评分,并记录药物不良反应。检测两组服药前及服药后第5天血细胞分析、血沉、C反应蛋白、肝功、肾功的变化。结果:与对照组相比,治疗组在缓解急性痛风性关节炎的炎症方面效果显著,治疗组C反应蛋白水平、血沉下降水平明显高于对照组(P<0.05);治疗组患者病变关节疼痛及肿胀程度与对照组相比明显缓解(P<0.05)。治疗组不良反应发生率为3.5%;对照组发生率为5.3%,差异无统计学意义。结论:环氧化酶-2抑制剂依托考昔治疗急性痛风性关节炎起效快,镇痛效果优于双氯芬酸钠,安全性及耐受性好。
Objective： To observe the efficacy and safety of COX-2 inhibitors etoricoxib in the treatment of patients with acute gouty arthritis. Methods： 113 patients with acute gouty arthritis were divided into two groups by andomized parallel control principle, etorieoxib group（120 mg/d, n=57） and Diclofenac sodium group （75 mg/d, n=56） as control. Two groups of patients were given the same basic treatment such as a low-purine diet, drink more water, bed rest, alkalization of urine. Pain scores and swelling scores of patients with lesions of the joints and adverse drug reactions were recorded at 0 hour, 4 hours, 2 days, 5 days after taking medicines. Blood cells, erythrocyte sedimentation rate, C-reactive protein, liver function, renal function were detected before taking mediciae and 5 days after taking in both groups. Results： Compared with the control group, etoficoxib group significantly alleviated the inflammation of acute gouty arthritis, C-reactive protein levels, erythrocyte sedimentation rate decreased significantly higher than that in the control group （P〈 0.05 ）. Pain and swelling degree of joints in etoficoxib group were alleviated significantly compared to the control group （P〈0.05）. The incidences of adverse reactions were not different in two groups, 3.5% in etoficoxib group, and 5.3% in the control group. Conclusions： Etoricoxib may be rapid onset and more effective than diclofenac for acute gouty arthritis in aspects of safety and tolerance.
出处
《现代生物医学进展》
CAS
2014年第29期5747-5750,共4页
Progress in Modern Biomedicine
基金
黑龙江省教育厅科学技术研究课题(12541520)
